Weight-loss drugs that are more potent than Novo Nordisk’s (NVO) Ozempic are being quickly developed, Peter Loftus of The Wall Street Journal reports. Following the success of Ozempic, researchers are trying to find the next generation of medicines to help people lose weight. Eli Lilly (ELI) recently presented data for an experimental treatment that could help people lose almost a quarter of their body weight in 11 months. A few of the companies developing drugs to surpass Ozempic include: Amgen (AMGN), Boehringer Ingelheim, Novo Nordisk, and Eli Lilly.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on NVO:
- Eli Lilly (NYSE:LLY) Touts Superior Results of Weight Loss Shot
- Pfizer’s (NYSE:PFE) Oral Obesity Drug Plans Get Leaner
- Cantor biotech/biopharma analysts hold analyst/industry conference call
- Drug makers are developing pill version of weight-loss drugs, WSJ reports
- EMA raises safety signal on Novo Nordisk drugs including Ozempic, Reuters says